Loading…
MapLight Therapeutics, Inc. is projected to rise to $16.48 by 2027, a +27% move from its current price of $13.02. MPLT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $11.91 | $13.02 | $14.24 | 0.00% |
| Aug 3 | $11.47 | $13.02 | $14.77 | 0.00% |
| Aug 4 | $11.15 | $13.02 | $15.20 | 0.00% |
| Aug 5 | $10.89 | $13.02 | $15.57 | 0.00% |
| Aug 6 | $10.66 | $13.02 | $15.90 | 0.00% |
| Aug 7 | $10.46 | $13.02 | $16.21 | 0.00% |
| Aug 8 | $10.28 | $13.02 | $16.49 | 0.00% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $10.28 | $13.02 | $16.49 | 0.00% |
| Week 2 | $9.32 | $13.02 | $18.19 | +0.01% |
| Week 3 | $8.65 | $13.02 | $19.61 | +0.01% |
| Week 4 | $8.12 | $13.02 | $20.89 | +0.01% |
| Week 5 | $7.67 | $13.02 | $22.10 | +0.02% |
| Week 6 | $7.30 | $13.02 | $23.24 | +0.02% |
| Week 7 | $6.97 | $13.02 | $24.34 | +0.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on patients suffering from debilitating central nervous system disorders. Its product portfolio includes ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company focused on central nervous system disorders. It currently trades at $13.02 per share, with a market capitalization of $590.4M and a rank of 2782.
The forecasted price path shows substantial upside over the coming years, with avg prices rising from $13.02 in 2026 to $31.42 by 2030 and to $128.93 by 2040, and to $275.72 by 2050. Longer-term ROIs accelerate, with 2030 ROI 141.3, 2040 ROI 890.3, and 2050 ROI 2017.7, and a bullish sentiment across 2027-2050.
A major floor 23.9% below — a decisive break under it would weaken the trend.
The nearest floor, 23.9% below — buyers have tended to step in here.
The nearest ceiling, 205.7% above — a clean break opens room to run.
A major ceiling 290.2% above — clearing it would confirm fresh momentum.
Key MPLT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MPLT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $12.86 | Buy | $16.33 | Sell |
| MA 10 | $24.48 | Sell | $21.68 | Sell |
| MA 20 | $31.07 | Sell | $26.78 | Sell |
| MA 50 | $30.49 | Sell | $29.18 | Sell |
| MA 100 | $27.72 | Sell | $27.60 | Sell |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.42 | Buy |
| Stoch RSI (14) | 19.16 | Buy |
| CCI (20) | -132.14 | Sell |
| Williams %R (14) | -88.88 | Info |
| MACD (12,26,9) | -3.01 | Sell |
| ROC (12) | -65.12 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 11.12 | Buy |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | -18.32 | Sell |
| Ultimate (7,14,28) | 22.23 | Buy |
| Momentum (10) | -24.85 | Sell |
| Aroon Osc (25) | -48.00 | Sell |
| Hull MA (9) | 7.88 | Buy |
| ADX (14) | 26.32 | Sell |
| ATR (14) | 2.70 | Info |
The near-term technical picture is neutral. RSI14 is 30 and the sentiment is NEUTRAL, with a 50-day simple moving average (SMA50) of $30.49. The 30-day range stretches from $7.22 to $23.47. Support sits at $9.90 and resistance is at $39.80. The stock also shows high volatility, with an annualized volatility metric of 200.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.90 | $13.02 | $19.49 | 0% | Neutral | |
| $10.88 | $16.48 | $27.02 | +27% | Bullish | |
| $11.33 | $19.01 | $33.95 | +46% | Bullish | |
| $11.89 | $21.85 | $41.60 | +68% | Bullish | |
| $15.70 | $31.42 | $63.03 | +141% | Bullish | |
| $19.28 | $41.89 | $87.85 | +222% | Bullish | |
| $24.32 | $54.04 | $117.79 | +315% | Bullish | |
| $26.43 | $58.74 | $132.53 | +351% | Bullish | |
| $23.25 | $51.67 | $118.84 | +297% | Bullish | |
| $28.47 | $63.28 | $145.53 | +386% | Bullish | |
| $58.02 | $128.93 | $296.55 | +890% | Bullish | |
| $124.07 | $275.72 | $634.15 | +20.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $9.90 | $13.02 | $17.51 | +0.00% |
| September 2026 | $11.08 | $13.88 | $18.38 | +6.61% |
| October 2026 | $10.18 | $13.03 | $17.74 | -6.16% |
| November 2026 | $9.95 | $12.95 | $18.03 | -0.58% |
| December 2026 | $10.38 | $13.72 | $19.49 | +5.99% |
Click any year to see its month-by-month MPLT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, MPLT is projected to trade between $9.90 and $19.49, averaging $13.02 — a potential gain of 0% from today's $13.02. Price action looks broadly range-bound.
MapLight Therapeutics, Inc.'s 2027 outlook centres on $16.48, within a $10.88 to $27.02 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, MPLT could reach as high as $33.95, with a base case around $19.01 and support toward $11.33 — roughly +46% from $13.02. Momentum favours further upside here.
Expect MPLT to range from $11.89 to $41.60 through 2029. The $21.85 average target implies a +68% move from current prices. That is up +15% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The MPLT price prediction for 2030 points to an average of $31.42 (low $15.70, high $63.03) — a potential gain of +141% on today's $13.02. Momentum favours further upside here.
In 2031, MPLT is projected to trade between $19.28 and $87.85, averaging $41.89 — a potential gain of +222% from today's $13.02. That is up +33% on the projected 2030 average. Buyers look set to stay in control over this stretch.
MapLight Therapeutics, Inc.'s 2032 outlook centres on $54.04, within a $24.32 to $117.79 range. That is up +29% on the projected 2031 average. That marks a +315% change versus current levels. Momentum favours further upside here.
By 2033, MPLT could reach as high as $132.53, with a base case around $58.74 and support toward $26.43 — roughly +351% from $13.02. Buyers look set to stay in control over this stretch.
Expect MPLT to range from $23.25 to $118.84 through 2034. The $51.67 average target implies a +297% move from current prices. That is -12% versus the projected 2033 average. Momentum favours further upside here.
The MPLT price prediction for 2035 points to an average of $63.28 (low $28.47, high $145.53) — a potential gain of +386% on today's $13.02. Buyers look set to stay in control over this stretch.
In 2040, MPLT is projected to trade between $58.02 and $296.55, averaging $128.93 — a potential gain of +890% from today's $13.02. That is up +104% on the projected 2035 average. Momentum favours further upside here.
MapLight Therapeutics, Inc.'s 2050 outlook centres on $275.72, within a $124.07 to $634.15 range. That is up +114% on the projected 2040 average. That marks a +20.2x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in MPLT today (≈ 76.804916 MPLT) could be worth
$21,176.49
+$20,176.49 (+2018%) by 2050 · US Dollar
Based on the average projected MPLT price of $275.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MPLTwould be worth at today's price.
$1,000 invested in MPLT on Oct 27, 2025 (≈ 54.525627 MPLT) would be worth
$709.92
-$290.08 (-29.0%) today · 0.71× · US Dollar
Based on a MPLT entry price of $18.34 vs. today's $13.02.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $36.56 | $356.13 | -64.4% |
| 1 month ago | $36.08 | $360.86 | -63.9% |
| 3 months ago | $30.7 | $424.1 | -57.6% |
| 6 months ago | $17.93 | $726.16 | -27.4% |
| All time ago | $18.34 | $709.92 | -29.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MPLT forecast.
Our base-case forecast reaches $26.00 around 2030.
Implied market cap at $26.00: $1.11B
The multi-year forecast portrays a bullish trajectory, with the 2027 Avg at $16.48 and 2027–2050 sentiment labeled BULLISH. Notably, the 2030 Avg is $31.42 with a 141.3 ROI, the 2040 Avg is $128.93 with an ROI of 890.3, and the 2050 Avg is $275.72 with an ROI of 2017.7. Other highlighted years show continued upside, including 2028 Avg $19.01, 2029 Avg $21.85, 2031 Avg $41.89, 2032 Avg $54.04, 2033 Avg $58.74, 2035 Avg $63.28, and 2034 Avg $51.67, all with bullish sentiment.
These are estimates, not guarantees, and reflect the modeled forecast. The asset exhibits high volatility potential, as indicated by the notable volatility metric, which underscores the possibility of substantial price swings.
Tap a question to reveal the answer.
2030 forecast: Min $15.70, Avg $31.42, Max $63.03, ROI 141.3, Sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward, with growing average prices (e.g., 2027 Avg $16.48, 2030 Avg $31.42, 2050 Avg $275.72) and rising ROIs (up to 2017.7 by 2050). These are estimates and not guarantees.
Yes. The forecast includes max values above $100: 2035 Max $145.53, 2040 Max $296.55, and 2050 Max $634.15.
Current price $13.02; Market cap $590.4M.
2040 forecast: Min $58.02, Avg $128.93, Max $296.55, ROI 890.3, Sentiment BULLISH.
MapLight Therapeutics, Inc. Community Discussion
0Share your MapLight Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.